Evicenter
MarkdownMedical informationP&T meetings
Ersodetug (RZ358)

Tumor hyperinsulinism

Manufacturer
Rezolute
Launch
Not announced
Last updated
140 sources

Clinical evidence

Expanded access program in Tumor hyperinsulinism

83 evidence topics · 17 sources

Objective
Location and study date
Status, dates, and location of the intermediate-size cohort expanded access program
FieldQuoted record
Expanded access status“Available”
Other study ID number“RZ358-303”
First submitted“2025-11-21”
First posted“2025-12-04”
Last update posted“2026-10-07”
Location“New Orleans, Louisiana, United States, 70112”
Study design
Eligibility criteria
Age and sex eligibility of the intermediate-size cohort expanded access program
FieldQuoted record
Ages eligible“18 Years and older”
Sexes eligible“All”
Treatment
Dose regimen by patient in the company table of 9 patients
Intervention in the intermediate-size cohort expanded access program
Study outcomes
Rationale for using discontinuation of parenteral glucose as the primary outcome
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Treatment duration and survival by patient in the company table of 9 patients
PatientTotal duration of ersodetug therapy (months)Overall survival (months)
Patient 1“13”“14”
Patient 2“5”“5”
Patient 3“5”“5”
Patient 4“14”“14”
Patient 5“22 (ongoing)”“22 (living)”
Patient 6“18 (ongoing)”“18 (living)”
Patient 7“6”“6”
Patient 8“1.5”“1.5”
Patient 9“10”“10”
Baseline characteristics
Demographics, tumor, and organ function by patient in the peer-reviewed case series
CharacteristicPatient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8
Gender; age (years)“M; 55”View highlighted excerpt for this quote“F; 50”View highlighted excerpt for this quote“F; 50”View highlighted excerpt for this quote“F; 43”View highlighted excerpt for this quote“M; 74”View highlighted excerpt for this quote“M; 62”View highlighted excerpt for this quote“F; 74”View highlighted excerpt for this quote“M; 24”View highlighted excerpt for this quote
Country“U.S.”View highlighted excerpt for this quote“U.S.”View highlighted excerpt for this quote“U.S.”View highlighted excerpt for this quote“U.S.”View highlighted excerpt for this quote“U.S.”View highlighted excerpt for this quote“U.S.”View highlighted excerpt for this quote“U.S.”View highlighted excerpt for this quote“The Netherlands”View highlighted excerpt for this quote
Race/ethnicity“White, Hispanic”View highlighted excerpt for this quote“White, Non-Hispanic”View highlighted excerpt for this quote“White, Non-Hispanic”View highlighted excerpt for this quote“White, Non-Hispanic”View highlighted excerpt for this quote“White, Non-Hispanic”View highlighted excerpt for this quote“White, Non-Hispanic”View highlighted excerpt for this quote“White, Non-Hispanic”View highlighted excerpt for this quote“White, Non-Hispanic”View highlighted excerpt for this quote
Diagnosis“Metastatic Insulinoma”View highlighted excerpt for this quote“Metastatic Insulinoma”View highlighted excerpt for this quote“Neuroendocrine Carcinoma of the Cervix”View highlighted excerpt for this quote“Metastatic Insulinoma”View highlighted excerpt for this quote“Metastatic Insulinoma”View highlighted excerpt for this quote“Metastatic Insulinoma”View highlighted excerpt for this quote“Metastatic Insulinoma”View highlighted excerpt for this quote“Metastatic Insulinoma”View highlighted excerpt for this quote
Diagnosis year“2021”View highlighted excerpt for this quote“2015”View highlighted excerpt for this quote“2022”View highlighted excerpt for this quote“2021”View highlighted excerpt for this quote“2023”View highlighted excerpt for this quote“2019”View highlighted excerpt for this quote“2022”View highlighted excerpt for this quote“2022”View highlighted excerpt for this quote
Tumor primary site“Pancreas”View highlighted excerpt for this quote“Pancreas”View highlighted excerpt for this quote“Cervix (neuroendocrine carcinoma)”View highlighted excerpt for this quote“Pancreas”View highlighted excerpt for this quote“Pancreas (primary pancreatic NET with liver metastases)”View highlighted excerpt for this quote“Pancreas (well-differentiated pancreatic NET)”View highlighted excerpt for this quote“Pancreas (well-differentiated NET in pancreatic body)”View highlighted excerpt for this quote“Pancreas (primary insulinoma diagnosed 2022; right-sided hemihepatectomy in 2024 at time of insulinoma)”View highlighted excerpt for this quote
Ki-67 (% and biopsy site)“8% (liver metastasis biopsy)”View highlighted excerpt for this quote“17.6% (liver resection specimen); primary pancreatic tumor Ki-67 9%”View highlighted excerpt for this quote“75% (liver metastasis biopsy)”View highlighted excerpt for this quote“5% (pancreatic primary tumor)”View highlighted excerpt for this quote“35% (liver metastasis; secondary tumor)”View highlighted excerpt for this quote“Unknown (fine-needle aspiration showing well-differentiated pancreatic NET)”View highlighted excerpt for this quote“42% (liver core needle biopsy; WHO grade 3 well-differentiated NET)”View highlighted excerpt for this quote“16% (pancreatic primary); 17.8% (liver metastasis)”View highlighted excerpt for this quote
Metastatic sites and burden“Multiple abdominal and multilobar hepatic lesions, abdominal pain”View highlighted excerpt for this quote“Liver, gastrohepatic lymph nodes, osseous metastases”View highlighted excerpt for this quote“Extensive metastatic burden (Multilobar liver and pelvic metastases)”View highlighted excerpt for this quote“Extesive metastatic burden (Liver, lymph nodes, bone)”View highlighted excerpt for this quote“Extensive liver tumor burden”View highlighted excerpt for this quote“Liver, periportal lymph nodes, para-aortic lymph nodes, low overall disease burden”View highlighted excerpt for this quote“Extensive bilobar hepatic metastatic burden; left hilar metastasis”View highlighted excerpt for this quote“Extensive liver tumor burden, involving an estimated 33% of the remaining left hemi-liver”View highlighted excerpt for this quote
Hepatic function at initiation“Mild ↑ transaminases, low albumin”View highlighted excerpt for this quote“Marked ↑ transaminases, low albumin”View highlighted excerpt for this quote“Mild ↑ in alk phos, low albumin”View highlighted excerpt for this quote“Marked ↑ alk phos, low albumin”View highlighted excerpt for this quote“Mild ↑ alk phos, low albumin”View highlighted excerpt for this quote“Modest ↑ transaminases”View highlighted excerpt for this quote“Moderate ↑ alk phos”View highlighted excerpt for this quote“Mild ↑ transaminases, and alk phos”View highlighted excerpt for this quote
ALT, AST (U/L)“81, 38”View highlighted excerpt for this quote“148, 144”View highlighted excerpt for this quote“22. 17”View highlighted excerpt for this quote“20, 53”View highlighted excerpt for this quote“36, 26”View highlighted excerpt for this quote“87, 75”View highlighted excerpt for this quote“44, 20”View highlighted excerpt for this quote“40, 44”View highlighted excerpt for this quote
Alkaline phosphatase (U/L)“105”View highlighted excerpt for this quote“620”View highlighted excerpt for this quote“173”View highlighted excerpt for this quote“677”View highlighted excerpt for this quote“108”View highlighted excerpt for this quote“104”View highlighted excerpt for this quote“255”View highlighted excerpt for this quote“161”View highlighted excerpt for this quote
Albumin (g/dL)“3.4”View highlighted excerpt for this quote“3.1”View highlighted excerpt for this quote“3.4”View highlighted excerpt for this quote“3.1”View highlighted excerpt for this quote“3.1”View highlighted excerpt for this quote“3.9”View highlighted excerpt for this quote“3.8”View highlighted excerpt for this quote“3.8”View highlighted excerpt for this quote
PT (sec)“NA”View highlighted excerpt for this quote“16.9”View highlighted excerpt for this quote“18.4”View highlighted excerpt for this quote“12”View highlighted excerpt for this quote“11.3”View highlighted excerpt for this quote“11.5”View highlighted excerpt for this quote“13.9”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote
INR (ratio)“1.1”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“1.0”View highlighted excerpt for this quote“1.0”View highlighted excerpt for this quote“1.2”View highlighted excerpt for this quote“1.1”View highlighted excerpt for this quote
Renal function at initiation“Normal”View highlighted excerpt for this quote“Normal”View highlighted excerpt for this quote“Impaired”View highlighted excerpt for this quote“Mildly impaired”View highlighted excerpt for this quote“Normal”View highlighted excerpt for this quote“Normal”View highlighted excerpt for this quote“Normal”View highlighted excerpt for this quote“Mildly impaired”View highlighted excerpt for this quote
Creatinine (mg/dL)“1.2”View highlighted excerpt for this quote“0.8”View highlighted excerpt for this quote“2.13”View highlighted excerpt for this quote“1.26”View highlighted excerpt for this quote“1.1”View highlighted excerpt for this quote“0.9”View highlighted excerpt for this quote“0.63”View highlighted excerpt for this quote“1.3”View highlighted excerpt for this quote
eGFR (mL/min/1.73 m2)“NA”View highlighted excerpt for this quote“90”View highlighted excerpt for this quote“49”View highlighted excerpt for this quote“54”View highlighted excerpt for this quote“>60”View highlighted excerpt for this quote“>60”View highlighted excerpt for this quote“93”View highlighted excerpt for this quote“73”View highlighted excerpt for this quote
Hospitalization, performance status, and prior antihypoglycemic therapy by patient in the peer-reviewed case series
CharacteristicPatient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8
Length of hospitalization before ersodetug (days)“28”View highlighted excerpt for this quote“NA (ambulatory)”View highlighted excerpt for this quote“15”View highlighted excerpt for this quote“49”View highlighted excerpt for this quote“34”View highlighted excerpt for this quote“NA (ambulatory)”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote“16”View highlighted excerpt for this quote
Hospice planning before ersodetug“Y”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote“Y”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote
Baseline ECOG“3”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Number of therapies for hypoglycemia (medications and IV glucose) before ersodetug“4”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote“5”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote
Diazoxide“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“Previously Tried”View highlighted excerpt for this quote“Previously Tried”View highlighted excerpt for this quote“Previously Tried”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote
Short-acting somatostatin analog (octreotide or pasireotide)“Previously Tried”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“Previously Tried”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“Previously Tried”View highlighted excerpt for this quote“Previously Tried”View highlighted excerpt for this quote
Long-acting somatostatin analog (lanreotide)“−”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“Previously Tried”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote
mTOR inhibitor (everolimus)“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote
Corticosteroid (dexamethasone, prednisone)“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“+”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote
GIR at ersodetug initiation (mg/kg/min)“6.0”View highlighted excerpt for this quote“7.0”View highlighted excerpt for this quote“5.1”View highlighted excerpt for this quote“6.2”View highlighted excerpt for this quote“4.9”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“5.6”View highlighted excerpt for this quote“3.1”View highlighted excerpt for this quote
Baseline characteristics by patient in the company table of 9 patients
Efficacy results
Time to discontinuation of each antihypoglycemic therapy by patient (days unless stated)
TherapyPatient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8
IV glucose“74 (slow taper)”View highlighted excerpt for this quote“139 (50% reduction)”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote“5”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“42”View highlighted excerpt for this quote
Diazoxide“111”View highlighted excerpt for this quote“10”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote“21”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“Ongoing”View highlighted excerpt for this quote
Short-acting somatostatin analog (octreotide or pasireotide)“NA”View highlighted excerpt for this quote“18”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote
Long-acting somatostatin analog (lanreotide)“NA”View highlighted excerpt for this quote“Ongoing”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“30”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“Ongoing”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote
mTOR inhibitor (everolimus)“∼6 months”View highlighted excerpt for this quote“18”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“Ongoing”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote“Ongoing”View highlighted excerpt for this quote“Ongoing”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote
Corticosteroid (dexamethasone, prednisone)“∼7 months”View highlighted excerpt for this quote“∼4 months”View highlighted excerpt for this quote“4 days”View highlighted excerpt for this quote“Ongoing”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“Ongoing”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote
Hospital discharge, tumor-directed therapy, performance status, and survival by patient
OutcomePatient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8
Time to discharge from hospital (days)“84”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“7”View highlighted excerpt for this quote“15”View highlighted excerpt for this quote“9”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“9”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Hospitalization days in month after initiation“30”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“7”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“16”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Chemotherapy within 8 weeks (yes/no; therapy)“Y; LuTate”View highlighted excerpt for this quote“Y; FOLFOX”View highlighted excerpt for this quote“Y; Pembrolizumab”View highlighted excerpt for this quote“Y; CAPTEM”View highlighted excerpt for this quote“Y; LuTate”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“Y; FOLFOX”View highlighted excerpt for this quote“Y; CAPTEM”View highlighted excerpt for this quote
Surgery within 8 weeks (yes/no; procedure)“N”View highlighted excerpt for this quote“Y; Whipple Surgery and Left Hepatectomy”View highlighted excerpt for this quote“Y; Total hysterectomy and bilateral oophorectomy”View highlighted excerpt for this quote“Y; Partial Pancreatectomy”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote“Y; Hemi-hepatectomy”View highlighted excerpt for this quote
Other medical procedure within 8 weeks (yes/no; type)“N”View highlighted excerpt for this quote“Y; HACE”View highlighted excerpt for this quote“N”View highlighted excerpt for this quote“Y; HAE”View highlighted excerpt for this quote“Y; HAE”View highlighted excerpt for this quote“Y; HAE”View highlighted excerpt for this quote“Y; HAE”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote
ECOG at 3 months“0”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Overall survival“14 months”View highlighted excerpt for this quote“5 months”View highlighted excerpt for this quote“5 months”View highlighted excerpt for this quote“14 months”View highlighted excerpt for this quote“17 months (living)”View highlighted excerpt for this quote“14 months (living)”View highlighted excerpt for this quote“6 months”View highlighted excerpt for this quote“10 months”View highlighted excerpt for this quote
Cause of death“Tumor progression”View highlighted excerpt for this quote“Tumor progression”View highlighted excerpt for this quote“Tumor progression”View highlighted excerpt for this quote“Tumor progression”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“MDS Progression/Sepsis”View highlighted excerpt for this quote“Tumor Progression”View highlighted excerpt for this quote
Continuous glucose monitoring parameters over 24 hours, by day, and by night
Period and parameterBaseline, 90 days before initiation: mean (min, max)Evaluable period, 90 days after initiation: mean (min, max)Relative change from baseline (%)Median change from baseline (90% CI)P value
24 hours: mean sensor glucose (mg/dL)“117.0 (86.9, 157.6)”View highlighted excerpt for this quote“138.0 (94.3, 189.5)”View highlighted excerpt for this quote“18.0”View highlighted excerpt for this quote“21.6 (6.5, 36.1)”View highlighted excerpt for this quote“0.02”View highlighted excerpt for this quote
24 hours: time above 180 (%)“10.1 (0.6, 29.3)”View highlighted excerpt for this quote“22.7 (0.2, 56.1)”View highlighted excerpt for this quote“124.4”View highlighted excerpt for this quote“13.5 (2.9, 24.3)”View highlighted excerpt for this quote“0.02”View highlighted excerpt for this quote
24 hours: time between 70 and 180 (%)“77.4 (61.0, 95.0)”View highlighted excerpt for this quote“69.2 (43.9, 87.3)”View highlighted excerpt for this quote“−10.6”View highlighted excerpt for this quote“−8.2 (−20.2, 4.8)”View highlighted excerpt for this quote“0.08”View highlighted excerpt for this quote
24 hours: time below 70 (%)“12.4 (1.7, 25.9)”View highlighted excerpt for this quote“8.0 (0.0, 22.4)”View highlighted excerpt for this quote“−35.6”View highlighted excerpt for this quote“−3.8 (−8.2, −1.1)”View highlighted excerpt for this quote“0.02”View highlighted excerpt for this quote
24 hours: time below 54 (%)“2.6 (0.0, 5.2)”View highlighted excerpt for this quote“1.9 (0.0, 6.8)”View highlighted excerpt for this quote“−29.2”View highlighted excerpt for this quote“−0.5 (−2.9, 1.3)”View highlighted excerpt for this quote“0.38”View highlighted excerpt for this quote
Day (06:00 to 00:00): mean sensor glucose (mg/dL)“117.2 (86.9, 155.7)”View highlighted excerpt for this quote“139.5 (99.0, 191.2)”View highlighted excerpt for this quote“19.0”View highlighted excerpt for this quote“21.8 (9.5, 36.9)”View highlighted excerpt for this quote“0.008”View highlighted excerpt for this quote
Day: time above 180 (%)“10.4 (0.7, 31.7)”View highlighted excerpt for this quote“23.2 (0.3, 57.7)”View highlighted excerpt for this quote“123.0”View highlighted excerpt for this quote“12.9 (3.8, 23.7)”View highlighted excerpt for this quote“0.02”View highlighted excerpt for this quote
Day: time between 70 and 180 (%)“76.8 (58.2, 95.0)”View highlighted excerpt for this quote“69.4 (42.3, 92.6)”View highlighted excerpt for this quote“−9.6”View highlighted excerpt for this quote“−6.2 (−19.7, 7.4)”View highlighted excerpt for this quote“0.25”View highlighted excerpt for this quote
Day: time below 70 (%)“12.8 (0.8, 27.5)”View highlighted excerpt for this quote“7.3 (0.0, 22.3)”View highlighted excerpt for this quote“−42.6”View highlighted excerpt for this quote“−4.6 (−11.6, −0.7)”View highlighted excerpt for this quote“0.02”View highlighted excerpt for this quote
Day: time below 54 (%)“2.7 (0.0, 4.5)”View highlighted excerpt for this quote“2.0 (0.0, 7.2)”View highlighted excerpt for this quote“−26.8”View highlighted excerpt for this quote“−0.7 (−2.8, 1.4)”View highlighted excerpt for this quote“0.46”View highlighted excerpt for this quote
Night (00:00 to 06:00): mean sensor glucose (mg/dL)“116.4 (87.0, 163.3)”View highlighted excerpt for this quote“134.2 (80.3, 196.6)”View highlighted excerpt for this quote“15.2”View highlighted excerpt for this quote“15.6 (−3.1, 43.2)”View highlighted excerpt for this quote“0.11”View highlighted excerpt for this quote
Night: time above 180 (%)“9.3 (0.0, 26.4)”View highlighted excerpt for this quote“21.6 (0.0, 57.4)”View highlighted excerpt for this quote“132.1”View highlighted excerpt for this quote“9.3 (0.6, 26.7)”View highlighted excerpt for this quote“0.02”View highlighted excerpt for this quote
Night: time between 70 and 180 (%)“79.3 (69.4, 95.0)”View highlighted excerpt for this quote“68.3 (42.0, 90.8)”View highlighted excerpt for this quote“−13.9”View highlighted excerpt for this quote“−7.5 (−23.9, −1.0)”View highlighted excerpt for this quote“0.02”View highlighted excerpt for this quote
Night: time below 70 (%)“11.3 (0.8, 26.0)”View highlighted excerpt for this quote“10.0 (0.0, 28.8)”View highlighted excerpt for this quote“−11.8”View highlighted excerpt for this quote“−1.1 (−4.5, 2.6)”View highlighted excerpt for this quote“0.25”View highlighted excerpt for this quote
Night: time below 54 (%)“2.5 (0.0, 7.6)”View highlighted excerpt for this quote“1.6 (0.0, 5.4)”View highlighted excerpt for this quote“−37.1”View highlighted excerpt for this quote“−1.1 (−4.8, 2.4)”View highlighted excerpt for this quote“0.55”View highlighted excerpt for this quote
Glucose infusion rate, hospitalization, and performance status outcomes by patient in the company table of 9 patients
OutcomePatient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8Patient 9
Percent reduction in GIR by 8 weeks“>50%, then 100% by 9 weeks”“<50%”“100%”“100%”“100%”“n/a”“100%”“Unknown amount”“100%”
Time to IV glucose discontinuation (days)“74”“139 (achieved 50% reduction)”“4”“5”“2”“n/a”“3”“n/a”“42”
Hospitalized days in the 30 days after initiation“30”“0”“7”“8”“8”“0”“16”“30”“1”
ECOG at month 3“0”“2”“0”“0”“0”“0”“1”“5”“0”
Single published case: hypoglycemia, dextrose infusion, and discharge after ersodetug
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-emergent serious adverse events, pooled cohort of 8
Study limitations
Summary
  • Design: the peer-reviewed report is a retrospective case series of 8 individuals treated under single-patient compassionate use, with no control group. The authors used nominal P-values without formal or prespecified hypothesis testing, could not construct 95% intervals, and developed the statistical analysis plan after the primary analyses.
  • Confounding: within 8 weeks of starting ersodetug, 7 individuals received chemotherapy, 4 had surgery, and 5 had other procedures such as hepatic arterial embolization, which can also reduce hypoglycemia. Doses and schedules changed during the program, and the first 2 individuals were treated under an earlier framework at a lower weekly dose.
  • Inconsistent counts and data: the number of patients differs by source (5 in the NANETS 2024 poster, 8 in the publication, 9 in the company table and ENDO 2026 poster). The company table and the publication differ in a patient's sex (“F; 74” and “M / 74”), and the publication gives hospitalization at entry as “median, 28 days; range, 4-66 days” in its text while its table lists a longest stay of 49 days. A company release describes the 9 patients as having malignant insulinoma and non-islet cell tumors, while the case-level tables list insulin-secreting tumors.
  • Overlap: the first patient's glucose data were previously published as a single case report, so that case is not independent evidence.
  • Safety ascertainment: disease progression was not reported as an adverse event under the program guidelines.